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We employ broadband dielectric spectroscopy to study the relaxation dynamics and 
crystallization kinetics of a broad-spectrum antibiotic, chloramphenicol, in its supercooled liquid 
form. Two dynamic processes are observed: the structural α relaxation, which becomes 
kinetically frozen at Tg = 302 ± 1 K, and an intramolecular secondary relaxation. Under 
isothermal conditions, the supercooled drug displays interconversion between different isomers, 
followed by recrystallization. Recrystallization follows the Avrami law with Avrami exponent n 
= 1.3 ± 0.1, consistent with a one dimensional growth of crystalline platelets, as observed by 
electron microscopy. Exposure to humid atmosphere and subsequent heating to high temperature 
is found to degrade the compound. The partially degraded sample displays a much lower 
tendency to crystallize, likely because the presence of the degradation products results in spatial 
frustration. This sample exhibits enhanced conductivity and an additional relaxation, 
intermediate to the ones observed in the pure sample, which likely corresponds to the non-
cooperative dynamics of the main degradation product. We find that dispersing the antibiotic in 
polylactic acid results in an amorphous sample which does not crystallize at room temperature 





Chloramphenicol (hereafter CAP, inset of Figure 1) is a broad-spectrum antibiotic used as a 
treatment for a number of bacterial infections. Although it had previously fallen into disuse due 
to limitations on the amount that can be applied not to cause systemic toxicity, it has become an 
alternative to treat multi-drug-resistant bacteria and has been recently suggested as a potential 
anticancer drug.1,2 CAP blocks protein growth, inhibiting peptide bond formation by binding to a 
peptidyl transferase enzyme of the bacterial ribosome, which prevents the transfer of aminoacids 
to the growing peptide chain. Thanks to this general mechanism, it proved effective against 
Gram-positive as well as Gram-negative (e.g. rickettsiae) bacteria.3  
CAP is hydrophobic, and shows a low aqueous solubility which limits its absorption rate. If a 
drug cannot be dissolved in biological fluids fast enough, it does not reach the absorption site 
and thus it does not trigger the desired biological response. Unfortunately, most drugs are poorly 
water-soluble, so that additional strategies must be employed to enhance their bioavailability.4 
Of the various possible approaches to enhance the solubility of active pharmaceutical 
ingredients, amorphization offers the advantage that it does not require chemical modification of 
the drug. Solid amorphous (glassy) pure drugs have a proven higher solubility in vivo as well as 
better dissolution profiles compared with the crystalline form of the drug.5,6,7,8,9,10,11,12 This is 
because the dissolution process is governed by the difference in Gibbs free energy of the initial 
and final state, i.e., between the separated components and the dissolved state, and the glassy 
state has higher free energy than the crystalline state, so that dissolution requires less energy, 
resulting in better rates of uptake by the organism. Several drugs with poor aqueous solubility 
have reached the drug development stage formulated as amorphous phase.13,14 
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On the other hand, glasses are thermodynamically unstable due precisely to their excess in free 
energy, entropy, and enthalpy, and are therefore susceptible to convert into the more stable and 
less soluble crystalline phase (by “recrystallization”). A large number of factors (such as 
preparation method, thermal and mechanical treatments employed during formulation, storage 
temperature, application of pressure or exposure to humidity, and even the choice of container 
material) may influence the kinetic stability of the glassy phase,15,16,17 and the microscopic 
mechanism governing metastability remains unclear. The two main aspects governing 
recrystallization are thermodynamics and molecular kinetics.18 The latter is known to influence 
the crystallization rate:19,20 for example, storage well below the glass transition temperature Tg 
(in fact, below the vitrification temperature of whole-molecule secondary relaxations) prevents 
recrystallization21,22 because, despite the fact that at such relatively low temperature the free-
energy difference between the crystalline and glassy phases (thermodynamic drive) is very large, 
the molecular mobility is too low for nucleation and growth of the crystalline phase to take place. 
In this context, it is important to identify, among drugs with low water solubility such as CAP, 
those which have sufficiently low recrystallization rate at room temperature so that they can be 
stored in glassy form for a convenient period of time. It is also interesting to devise strategies to 
improve the physical stability of those which instead tend to recrystallize from their amorphous 
state over short times. In the case of CAP, a recent study by means of broadband dielectric 
spectroscopy23,24 has shown that the amorphous phase of CAP can be heated to and maintained 
at temperatures well above its glass transition temperature (Tg = 300 K) without any visible sign 
of recrystallization.25 This result is very interesting in view of the low aqueous solubility of this 
antibiotic, and it is moreover puzzling in light of the fact that an earlier study26 on CAP has 
instead shown that recrystallization above Tg proceeds so fast that complete crystallization is 
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observed in calorimetry thermograms obtained while heating from the glass state at a rate of 10 
K/min already at Tg + 25 K. 
Recrystallization of a supercooled liquid can be hindered through spatial frustration, since in 
such case the molecules cannot aggregate to form an ordered structure. For example, two-
component amorphous mixtures have been shown to remain stable even at temperatures where 
both pure components recrystallize (the first studies of binary mixtures go back to the 1960’s 
27,28). The authors of the afore-mentioned recent study of kinetically stable supercooled liquid 
samples of CAP have proposed that the metastability of their samples may be due to spatial 
frustration associated with the presence, in the sample, of different tautomeric forms of the 
drug.25 We show here that the observed metastability of CAP is indeed due to spatial frustration, 
but that it is due to the presence of hydrolysis products. We find evidence for the same 
tautomeric transformations also in supercooled liquid samples of CAP that do crystallize. 
We find that recrystallization of pure CAP takes place on the timescale of hours at 
temperatures higher than Tg. At room temperature (just below Tg) glassy CAP is found to 
crystallize in a timespan of days, which indicates that refrigeration would be needed to prevent 
the amorphous drug to crystallize. The crystallization kinetics follows the Avrami law with 
exponent n equal to 1.3, corresponding to one-dimensional (fibrillar) growth with only sporadic 
nucleation. On the other hand, we show that the metastability of amorphous CAP can indeed be 
tuned employing different strategies. We find that humid CAP degrades when heated above its 
melting temperature (degradation of CAP was previously observed when the drug was exposed 
to chlorine and UV radiation or in aqueous media29,30,31,32,33). The resulting glass, which is in 
fact a mixture of CAP and degradation products, does not seem to crystallize over short times. 
These findings can rationalize the recent report of a lack of recrystallization of supercooled 
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liquid CAP.25 If it can be shown that the hydrolysis products are unharmful, then this strategy 
may be a simple and viable one to obtain kinetically stable amorphous CAP samples. We show 
moreover that CAP remains amorphous also when mixed with a biocompatible polymer such as 
polylactic acid, likely due to spatial frustration. 
Materials and Methods 
Chloramphenicol (C11H12Cl2N2O5, Mw =323.13 g/mol) was purchased from Sigma-Aldrich 
with a purity higher than 98% and stored in air at ambient temperature. Three types of CAP 
samples were measured. In one case the CAP powder was initially dried in a vacuum oven for 24 
h at room temperature and then melted and rapidly cooled to obtain a glass. In the second case, 
the powder was melted directly after retrieval from its storage bottle in air. In order to check the 
effect of water on crystallization, a third type of CAP sample was prepared by melting an oven-
dried sample and then allowing it to crystallize in water-vapor saturated atmosphere. For 
broadband dielectric spectroscopy (BDS) experiments, the powder was melted directly between 
the stainless steel electrodes of the capacitor (details are given in the following paragraph) and 
cooled at a rate of approximately 10 K/min. For differential scanning calorimetry (DSC) 
experiments, the powder was either melted directly during the first DSC scan (first and second 
type), or melted outside in the DSC pan (third type).   Finally, binary mixtures of CAP with poly-
lactic acid (PLA) were obtained by dissolving PLA (grade 4032D, from Natureworks LLC, 
USA, a semi-crystalline material with a concentration of D enantiomers less than 2%), in 
chloroform and letting it dissolve overnight using a magnetic stirrer at 310 K. The correct 
amount of CAP to achieve a drug loading of 20wt-% in PLA was then dissolved in acetone and 
such solution was then mixed with the PLA/chloroform mixture. Films were prepared by solvent 
casting directly on metal disk electrodes, followed by heating to 433 K to allowall solvents to 
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evaporate and to melt the crystalline fraction of PLA formed during solvent evaporation.  
Characterization by X-ray diffraction showed the obtained mixture to be amorphous, and to 
remain so during long periods of time of storage at room temperature. 
Differential scanning calorimetry (DSC) experiments were carried out on different CAP 
samples in open aluminum pans (diameter 4 mm) under nitrogen atmosphere, by means of a 
Q100 calorimeter from TA Instruments. Measurements were performed using a heating/cooling 
rate of 10 K/min and drug mass around 10 mg. 
Infrared absorption spectra were recorded in the 4000–600 cm− 1 range with a Fourier 
Transform FTIR 4100 Jasco spectrometer equipped with a Specac model MKII Golden Gate 
attenuated total reflection (ATR) cell. 
A Novocontrol Alpha analyzer was used for broadband dielectric spectroscopy (BDS) 
measurements. The sample was placed in a stainless steel parallel-plate capacitor (diameter of 
1.2 cm) specially designed for the analysis of liquid samples, with the two electrodes kept at 
fixed distance by means of silica spacers of 50 μm diameter. Temperature control of the 
capacitor and thus of the sample was achieved with a nitrogen-gas flow cryostat with an error not 
higher than 0.3 K. Two different types of BDS experiments were carried out, in order to study 
the relaxation dynamics and the crystallization kinetics of the material. In the first case, the 
previously dried or as-stored polycrystalline powder sample was placed in the capacitor, melted 
at 423 K and quenched to cryogenic temperature inside the cryostat. Successive isothermal 
measurements were done every 10 K, from 133.2 to 233.2 K, every 5K, from 243.2 to 298.2 K, 
every 2 K, from 303.2 to 328.2 K, and again every 5 K, from 333.2 to 373.2 K. All 
measurements were done in the frequency (ν) range between 10−2 and 106 Hz. 
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The second type of BDS experiment, designed to study the isothermal crystallization kinetics 
of CAP, consisted of measuring the decrease of strength of the dielectric loss as a function of 
time during the crystallization of the supercooled material at different (fixed) temperatures. To 
this end, the molten sample was placed inside a precooled cryostat at 293.2 K (i.e., about 8K 
below Tg) and then the temperature was raised at a rate of 10 K/min until reaching the desired 
isothermal crystallization temperature. We measured the recrystallization at five distinct 
temperatures between 319 and 335 K by acquiring several dielectric spectra one after another, in 
the frequency range from 1 to 106 Hz.  A freshly prepared sample was used for each isothermal 
recrystallization experiment. 
To obtain relaxation time values and quantify the changes in relaxation dynamics, we fitted the 
dielectric spectra (real and imaginary part simultaneously) with a power law for the conductivity 
contribution and a superposition of Havriliak-Negami functions34,35 for the relaxation peaks. The 
analytical expression of the Havriliak-Negami function is: 




Hereω = 2πν is the angular frequency,ε∞ is the permittivity in the high frequency limit, Δε is 
the dielectric strength, the exponents a and b (which may vary between 0 and 1) describe the 
symmetric and asymmetric broadening of the peak, respectively, and τHN is a time parameter 
connected to the characteristic relaxation time τmax, corresponding to the maximum of the 
relaxation time distribution. τmax was calculated from the fitting parameters as: 











Specific cases of this relaxation are the Cole-Cole (CC)36 and Cole-Davidson (CD)37 
relaxations, which are obtained for b = 1 and a = 1, respectively. For both cases τmax = τHN. Most 
secondary peaks are broad but symmetric, and are often described with the Cole-Cole function.  
Results and Discussion 
The blue line in Figure 1a represents the DSC thermogram of the pure (vacuum-dried) CAP 
powder, measured upon heating. The observed onset of melting is 422 ± 1 K, in agreement with 
previous findings,26 with a enthalpy of fusion of 103 ± 3 J/g. X-ray diffraction patterns of the 
vacuum-dried powder are in agreement with previous findings.38 The glass transition 
temperature, identified in the second heat-up scan acquired after cooling the melted sample 





Figure 1. DSC thermograms, obtained by heating at 10 K/min, of pure CAP (blue) and CAP 
recrystallized from the glass in humid atmosphere and stored under humid conditions for 3 days 
(red). The upper panel shows the melting run, where the onset of melting is indicated. The lower 
panel shows the second run after melting, where the glass transition temperature is indicated. 
Inset to upper panel: molecular structure of CAP. 
A second sample was prepared by melting the powder in an open DSC pan, cooling the 
resulting liquid to the glassy state and then storing it for 3 days in a water-vapor saturated 
atmosphere. The resulting sample had fully recrystallized (red line in Figure 1a). The melting 
temperature of the sample recrystallized in the presence of water saturated atmosphere is 416 ± 1 
K and the enthalpy of fusion is only 87 ± 3 J/g. The X-Ray diffraction patterns of this 
recrystallized phase are virtually identical to those of the pure vacuum-dried powder, showing 
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that no hydrate phase39 was formed in the sample recrystallized in water saturated atmosphere. 
The lower melting point and enthalpy observed in Figure 1a are likely due to a decrease of the 
purity of the sample. Full recrystallization was observed also in glassy samples stored in air at 
room temperature over a period of few days. These results confirm that cold recrystallization of 
CAP is possible even in the glassy state, that is, that glassy CAP is unstable against the formation 
of the crystal phase. 
We employed dielectric spectroscopy to study the molecular relaxation dynamics of 
amorphous CAP (both in the supercooled liquid and glassy state). The vacuum-dried CAP 
powder was melted and fast-cooled to 133 K, and isothermal spectra were then acquired by 
stepwise increasing the temperature. Figure 2 shows the dielectric loss spectra at selected 
temperatures. Panel b shows the spectra above room temperature, in which the structural 
relaxation is visible on top of a conductivity background which increases towards low 
frequencies. This relaxation is the-so called primary α process, which corresponds to the 
cooperative motion of CAP molecules and is associated with the glass transition. The peak 
maximum of the α relaxation moves to lower frequencies the lower the temperature, indicating 
decreasing molecular mobility with decreasing thermal energy, and it is below 0.01 Hz for T < 
302 K, in agreement with the calorimetric Tg.26 Figure 2a shows the spectra below Tg, where a 
secondary (γ) relaxation much less intense than the α process is observed. 
The primary relaxation was fitted to a Havriliak-Negami function, and the best fit was obtained 
with a Cole-Davidson function (a = 1), with b varying monotonically between 0.59 and 0.65. 
The secondary relaxation was fitted with a Cole-Cole function (b = 1) and the resulting shape 
parameter a varied between 0.18 and 0.3. 
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Figure 2. Selected dielectric loss spectra of pure CAP between 133 and 243 K (a) and between 
303 and 328 K (b). Low frequency data in (a) have been smoothed. 
The relaxation times of both processes are displayed as Arrhenius plot in Figure 3. The inset to 
Figure 3 displays the relaxation strength of the α relaxation for temperatures just above Tg. It can 
be seen that the relaxation strength of the α process scales as 1/T, as expected from the 
Kirkwood-Fröhlich equation.34 The secondary relaxation is a simply-activated process, following 
13 
the Arrhenius law with activation energy Ea = 38.0 ± 0.6 kJ/mol, a relatively low value which is 
close to that reported in ref 25 and which suggests an intramolecular origin of this relaxation 
process,40 as also discussed below. Instead, the temperature dependence of the α relaxation time 
could be modeled with a Vogel-Fulcher-Tamman (VFT) function, defined by: 






Here τ∞ is the high temperature limit of the relaxation time, D is the so-called strength 
parameter (proportional to the inverse of the fragility index, see below) and T0 is the Vogel-
Fulcher temperature, whose value indicates the departure from a simply-activated behavior. The 
obtained values were Log(τ∞/[s]) = –15.0 ± 0.7, D = 7.6 ± 0.8, T0 = 253 ± 3 K. The estimated 
glass transition temperature, defined as customary as the temperature at which τα reaches 100 s, 
was 302.0 ± 0.5 K, in agreement with the DSC results of Figure 1. 
From the fit we can obtain the fragility index of amorphous CAP, which is defined as 





The fragility value obtained from the slope of a linear fit near Tg is m = 104 ± 2, which is in 
agreement with the one calculated directly from the fit parameters m = (D/ln10)·((T0/Tg)/(1–
T0/Tg)2) = (1.1 ± 0.2)·102. CAP is hence a rather fragile glass-former. 
The corresponding α relaxation times and VFT parameters reported in ref. 25 are slightly 
different; in particular, the authors of this work found a fragility of m = 116. This discrepancy is 
probably related to the fact that the sample characterized by Paluch and coworkers was partially 
degraded, as discussed in the following. 
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Figure 3. Relaxation map of pure CAP. Blue (resp., black) squares represent the α (resp., γ) 
relaxation. Continuous lines are fits with a VFT function (orange line) and an Arrhenius function 
(purple line), respectively. Inset: Temperature dependence of the dielectric strength of the α 
relaxation below the onset temperature of recrystallization. 
The relaxation dynamics could not be explored at higher temperature. At 315 K, in fact, a clear 
decrease of the loss peak maximum is visible (Figure 2b), indicative of the occurrence of 
recrystallization. The intensity of the relaxation (dielectric strength) is directly proportional to 
the number of relaxing dipoles in the sample34 and recrystallization implies loss of orientational 
motions. Since the viscosity is lower at higher temperatures, recrystallization, whose kinetics is 
mostly governed by molecular diffusion, is more likely to take place above Tg. This rationalizes 
the fact that the decrease in dielectric strength is only observed at high temperatures, where 
crystallite nucleation and growth take place and molecular dipoles become immobilized.41,42 
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Figure 4. Dielectric spectra of the real (top panels) and imaginary part (bottom panels) of the 
dielectric permittivity of CAP at 319 K at different times as indicated, during isothermal 
tautomerization (a) and subsequent recrystallization (b). 
We performed isothermal recrystallization measurements to investigate the characteristic 
timescale and mechanism of crystal growth from the supercooled liquid phase. Figure 4 show 
dielectric spectra as a function of time, recorded at 319 K. Similar to what was reported in ref 25, 
we observe an initial increase in the spectral intensity (in the first isothermal spectra recorded, 
see Figure 4a), which is most likely due to the tautomerization process proposed in ref 25, which 
involves transformation between three distinct molecular isomers of CAP. The dielectric strength 
is proportional to the number of dipolar molecules in the sample times the square of the dipole 
moment; since the total number of molecules in the sample is not changing, the only possible 
16 
explanation of the increase in the strength is that the molecular dipole changes, as already argued 
in ref 25. The origin of the increase of dielectric strength is then ascribed to an increase in the 
molecular dipole moment as the population of tautomers changes over time. In particular, by the 
authors of ref 25 suggested two paths of tautomerization: the amide-imidic acid and the keto-enol 
tautomerization. According to their DFT study, of the three tautomers, the enol form has the 
highest molecular dipole, the amide/keto form has the lowest dipole moment, while the imidic 
acid form has a value of dipole moment that is intermediate between the former two. It would 
thus appear that the number of enol and/or imidic acid tautomers is increasing with time as liquid 
CAP is supercooled and held at isothermal conditions above Tg. The origin of the 
tautomerization process is likely the different equilibrium value of the tautomer concentrations 
above the melting point (concentrations which are likely maintained during the rapid quench to 
below Tg) and in the supercooled liquid state below the melting point.25 
After tautomer transformations have ended, i.e., after a stationary static permittivity value is 
reached, one can observe, in the same isothermal series of spectra, the decrease of spectral 
intensity with time due to recrystallization, a decrease visible both in the real (top panel of Figure 
4b) and in the imaginary (bottom panel) part of the dielectric spectra. This observation rules out 
the hypothesis, brought forth in ref 25, that that the changes induced in the sample by isomeric 
transformation of CAP are sufficient to hinder its recrystallization. 
The evolution of crystallization is best analyzed looking at the dielectric strength Δε, which as 
mentioned is directly correlated to the number of relaxing molecules. Because the real and 
imaginary parts of the permittivity are related by Kramers-Kronig transformation, the dielectric 
strength of a relaxation (area below the peak in the loss spectrum) is Δε= εs – ε∞, that is, it is 
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equal to the difference between the static (real) permittivity εs and the high frequency limit of the 
real part of the permittivity, ε∞. The so-obtained dielectric strength is shown as function of time 
in Figure 5a. The width of the relaxation was found to grow over time (as the b parameter of the 
Cole-Davidson function lowers, not displayed) probably indicating that, while recrystallization 
develops, the scattering in the distribution of sizes of the amorphous domains increases.43 
The crystallization kinetics can be followed through the normalized static permittivity 
difference, defined as:44 




where εs(L) is the static permittivity of the (supercooled) liquid and εs(C) is the static 
permittivity of the crystal, while εs(t) is the static dielectric permittivity of the sample measured 
at the time t from the start of the isothermal measurement. For each isothermal recrystallization 
temperature, the values of εs were taken at a distinct fixed frequency in the range between 1 and 
10 Hz, but always corresponding to the low frequency plateau value of ε’. 
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Figure 5. (a) Dielectric strength ∆εα of the structural relaxation of CAP as a function of time for 
the isotherms at 319 (blue) and 324 K (red).The arrows indicate the onset time of crystallization 
(to). Inset: scanning electron microphotographs of CAP crystallites formed by recrystallization 
from the melt. (b) Avrami plot of isothermal experiments at 319 (blue), 324 (red), 327 (cyan), 
and 330 K (orange). Lines represent linear fits. Inset: correlation of the crystallization time tc – to 
with the structural relaxation time τα. 
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Assuming a temporal dependence of recrystallization as described by Avrami,45,46 εn is given 
by:47 
(eq 6) 𝜀𝑛(𝑡) =  1 − exp(−𝐾(𝑡 − 𝑡o)𝑛) 
Here, to is the onset (induction) time of nucleation, K is the rate of recrystallization and n is the 
Avrami exponent which depends only on the morphology of crystallites and the mechanism of 
the recrystallization process.48 The value of to is estimated taking the intercept of the horizontal 
plateau of Δε at short times with the tangent to the decreasing portion of the graph of Δε (see 
Figure 5a). Figure 5b shows the plot of ln(–ln(1–εn)) versus ln(t– to) for four isothermal 
measurements. The observed linear dependence confirms the validity of Avrami’s law. The slope 
of the fit gives the parameter n, and the intercept is ln(K). The Avrami exponent is n = 1.3 ± 0.1, 
and it is constant (within experimental error) for all four isothermal conditions considered. A 
value in this range indicates predominant growth of the crystal nuclei in one dimension, in the 
form of dentritic structures of needle-like to rod-like or even laminar crystallites. This is 
confirmed by the insets to Figure 5a, which displays two SEM microphotographs of CAP 
crystallites formed by recrystallization of the supercooled liquid. Similar crystallite shapes were 
reported also in previous studies on the as-synthesized CAP powder.49  
The inset of Figure 5b shows the relation between Logτα and Log(tc – to), where tc is the 
characteristic crystal growth time, defined as the time at which εn becomes equal to 0.25. Though 
not precise, the linear regression gives a slope value of 0.6 ± 0.1. This correlation between the 
structural relaxation time and the time of crystallization has been observed before (albeit with a 
slightly different slope) in several systems, for example in the case of stiripentol20 and of 
indomethacine and celecoxib,50 and also in binary mixtures of pharmaceutical compounds and 
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polymeric excipients.51 The correlation between crystal growth rate and mobility (or 
equivalently, viscosity) above Tg appears to be a general feature of glass formers (also non-
pharmaceutical ones),41,52,53 related to the fact that the crystallization rate is kinetically driven 
near the glass transition temperature.  
As mentioned, previous dielectric measurements25 at ambient pressure showed no 
recrystallization of CAP, which was ascribed to the effect of conformational changes 
(tautomerization) in the supercooled liquid sample. The authors of this previous study report that 
no crystallization takes place at 323 K during at least two and a half days, and they report that no 
crystallization takes place at 338 K during at least three hours. Instead, Figure 5 shows that pure 
CAP crystallizes relatively fast at 324 K, and our experiments at 335 K (not shown) indicate that 
crystallization at this temperature is so fast that it starts well before reaching the isothermal 
temperature conditions. As we show in the following, the most likely explanation of the failure 
of CAP to recrystallize in the experiments reported in ref 25 is its partial degradation. 
Previous studies have shown that CAP has two main degradation pathways, namely, amide 
hydrolysis and carbon-chlorine cleavage.29,30,31,32 In the former case the reaction is acid-base 
catalyzed (though its rate does not depend on the pH of the concentration) while in the latter 
case, pH and temperature play a significant role. In the former case, the products of degradation 
are 1-(p-nitrophenyl)-2-amino-propanediol and dichloroacetic acid, while in the latter case they 
are a Cl-substituted alcohol CAP derivative and (at least partially) dissociated hidrochloric 
acid,30 but other secondary pathways that lead to degradation may exist.29 Furthermore it was 
reported that, while water-free preparations show no sign of degradation (pure CAP does not 
degrade upon melting54), detectable amounts of these degradation products are present in 
aqueous solutions as well as in preparations of CAP with relatively low amounts of water (e.g., 
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condensed from humid air). Recent studies55,56 report that the half-life of CAP in water at 333 K 
is of the order of 20 days, and that in boiling water CAP exhibits 12% degradation in 1 hour. 
Dielectric measurements on the as-stored CAP powder (without prior drying in the vacuum 
oven) indicate that it indeed does not recrystallize, or else recrystallizes at a much slower rate, 
than the pure (vacuum dried) material. Figure 6a shows isothermal dielectric measurements at 
324 Kon a supercooled liquid sample of CAP melted at 433 K directly after retrieval from the 
storage bottle (in air). After 768 min, Δε as detected from the real permittivity spectra is lowered 
by only 5% with respect to its value at the beginning of the experiment, while no clear difference 
is detected in the imaginary permittivity (loss) spectra. After 977 min a slight difference is 
observed in the loss spectra, and Δε is lowered only by 8%.This is clearly in contrast to what is 
observed in Figures 4 and 5: for example, when the vacuum-dried sample is melted at 423 K, 




Figure 6. (a) Dielectric loss spectra of CAP measured at 324 K, respectively 7 (black), 768 
(blue) and 977 (red) minutes after reaching this temperature from the glassy state. The upper 
inset shows the corresponding ε’ spectra, while lower inset shows the dielectric strength as 
function of time. (b) Comparison between the dielectric loss of the partially degraded (black) and 
pure CAP (blue), at two temperatures, above (317 K) and well below (203 K) the glass transition 
temperature. Inset: comparison at 317 K between the dielectric loss spectrum of the pure sample 
and the Kramers–Kronig transformation of the real permittivity spectrum of the degraded 
sample. 
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A possible rationale for the hindering of recrystallization could be that heating the initially 
water containing powder leads to partial degradation, and that the products of degradation 
impede the ordering of the CAP molecules into a crystalline phase. In other words, just like 
many binary mixtures fail to recrystallize due to the extremely slow formation kinetics (or lack) 
of a co-crystal phase, it can be expected that CAP does not recrystallize when mixed with the 
products of degradation such as for example the 1-(p-nitrophenyl)-2-amino-propanediol 
molecules. The occurrence of partial degradation was confirmed by direct observation of the 
sample at the end of the experiment: while pure CAP is white, the outcome of melting the as-
stored CAP sample was a viscous yellow-brownish liquid, with a color similar to that previously 
reported for sunlight degraded CAP.29 To analyze the outcome of degradation, we have recorded 
the FTIR spectrum of the degraded sample (after annealing for 3600 s at 433 K) and compared it 
to the spectrum of the pure (vacuum-dried) sample. As can be seen from Figure 7, the amide A 
(3130-3500 cm–1) and amide II (around 1500 cm–1) bands were modified after annealing, with 
the degraded sample showing much broader and less defined peaks. The first amide band shows 
clearly how hydrogen bonding network is affected by the high temperature treatment, as the two 
defined peaks that are visible in the pure sample at 3258 and 3343 cm–1 merge into a broader and 
wider band. 
We therefore suggest that the observed stability of supercooled CAP obtained by melting the 
as-stored powder is indeed due to spatial frustration, but not due to the presence of different 
tautomers, as suggested in ref 25, and instead due to the presence of hydrolysis products. 
Tautomerization transformations are observed also in pure (non-degraded) CAP, and they result 
in samples that crystallize above Tg over relatively short periods of time. Hence it would appear 
that the presence of different tautomers is not an impediment for nucleation of the crystal phase. 
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Figure 7. Comparison of the FTIR spectra of pure CAP (black) and degraded CAP (red dotted 
line). 
To assess how degradation influences the dynamics and allow further comparison with the 
results of ref 25, we performed dielectric spectroscopy measurements on a (partially) degraded 
sample. This sample displayed the same primary and secondary relaxation as pure CAP (Figure 
8a). As can be seen from Figure 6b, the loss spectrum of the degraded sample was characterized 
by a higher conductivity, most likely due to charged products of the water-induced partial 
decomposition (such as protons and hydroxyl and chlorine anions), which lowers the visibility of 
the structural relaxation peak. In order to allow a better comparison of the spectra, the inset of 
Figure 6b displays the approximate Kramers-Kronig transformation of the real part of the 
dielectric constant,57,58 together with the loss spectrum of the non-degraded sample at the same 
temperature. The relaxation times are virtually identical. This can be clearly observed in the 
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comparison of the relaxation maps of both samples, displayed in Figure 8a. Both the structural 
relaxation times and those of the secondary relaxation in the glassy state are seen to coincide 
roughly in both samples (and with the relaxation times reported in ref 25, not shown), indicating 
that the quantity of degraded molecule is not enough to affect the cooperative dynamics of the 
sample. 
On the other hand, the partially degraded sample also exhibits another secondary relaxation, 
which is absent in non-degraded CAP, as visible directly in the comparison of the respective 
spectra at 203 K shown in the inset to Figure 8a. The activation energy of this (slower) secondary 
process is Ea = 65.0 ± 0.8 kJ/mol. In the main panel we show the prediction of the so-called 
Coupling Model, which has been found to describe in many instances the properties of the 
Johari-Goldstein relaxation of molecular glass formers.59,60 The relaxation time of the secondary 
relaxations is far from that predicted by the Coupling Model, which shows that neither is a 
Johari-Goldstein relaxation. Hence the additional dynamic process observed in the partially 
degraded sample must have a different origin. 
The observed activation energy and relaxation times suggest that this process could be due to the 
(non-cooperative) relaxation dynamics of degradation products present as impurities in the 
sample. The 1-(p-nitro-phenyl)-2-amino-propanediol moieties, for example, are present in lower 
concentration and have lower mass than CAP, which would rationalize why the new relaxation 
follows an Arrhenius behavior with faster times compared with the structural ones. Similarly, as 
mentioned previously, the presence of ionic degradation products rationalizes the increase in 
conductivity observed in partially degraded CAP. Figure 8b shows the Arrhenius plot of the dc 
conductivity (σdc) of both pure and partially degraded CAP, identified as the plateau value of the 
real part of the conductivity spectra (defined by the relation σ’(ω) = ωε0ε’’(ω)). 
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Figure 8. (a) Relaxation map of the pure (open symbols) and partially degraded (filled symbols) 
amorphous CAP samples. Triangles represent the α relaxation, while squares and circles 
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secondary relaxations. The solid line is the fit with the VFT eq. 3, while dashed lines represent 
Arrhenius fits of secondary relaxation times. Open stars represent the relaxation time of the 
Johari-Goldstein relaxation predicted by the Coupling Model. Inset: comparison of the loss 
spectra of the pure and degraded sample at T = 203 K. (b) Arrhenius plot of the dc conductivity 
of both amorphous samples. Inset: sublinear dependence between the dc conductivity and the 
relaxation time of the structural process in the partially degraded sample. 
The dc conductivity of the partially degraded sample is significantly higher, it does not exhibit 
a monotonic behavior (in fact, it decreases above 384K), and, as visible in the inset to Figure 7b, 
it does not scale linearly with the cooperative relaxation time (rather, it displays a power law 
correlation with it, referred to fractional Stokes-Einstein rule61). These last two observations 
suggest that the conductivity enhancement is due to relatively small, ionic species (for example, 
chlorine ions, hydroxyl ions, or protons) whose diffusion is decoupled from the structural 
relaxation of the much bulkier CAP molecules,62 and which likely recombine into neutral species 
upon heating to above approximately 380 K. Other glass-forming systems show a decoupling of 
ion conduction and structural relaxation, in particular ionic liquids, where various processes are 
responsible for conduction.63 
Even though the partially degraded pharmaceutical is stable in the amorphous phase, another 
approach should be taken to stabilize the amorphous form of CAP, so as to take advantage of its 
better dissolution profile with respect to the crystalline form, and at the same time avoid the 
potential toxicity of the degradation products. A strategy that suggests itself in the case of CAP is 
to mix it with another (biocompatible) substance that could induce spatial frustration as in the 
partially degraded sample.64 To demonstrate the feasibility of this approach, we dispersed CAP 
(20% in weight) in a commercial biopolymer, namely poly-lactic acid (PLA), which due to its 
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biocompatibility, degradation into natural metabolites and low cost, is one of the most widely 
used materials in biomedical applications.65,66 
The left inset to Figure 9 shows the DSC thermogram of the resulting amorphous solid-state 
dispersion, whose Tg is observed to be 316 K, in between the Tg of pure PLA (332 K) and that of 
CAP (302 K). At higher temperature, only the recrystallization and subsequent melting of PLA 
can be seen. Interestingly, both the Tg and melting temperature of PLA seem to be affected by 
the presence of the drug. The onset of PLA recrystallization occurs at relatively high temperature 
(ca. 380 K), hence it does not affect the storage and metastability of the amorphous 
pharmaceutical at ambient temperature. As visible in the dielectric spectra displayed in Figure 9, 
at a given temperature the structural relaxation peak of the mixture is observed at a frequency in 
between the peak of pure PLA and the peak of pure CAP, as expected from the observed 
variation in Tg. No phase separation is observed: only one Tg is detected in DSC, and only one 
structural loss peak is observed in BDS. The right inset of Figure 9 shows the Arrhenius plot for 
the three samples, where again the relaxation times of the dispersion are seen to lie in between 
the relaxation times of the polymer and of pure CAP. This totally amorphous and homogeneous 




Figure 9. Comparison of the loss spectra at 338 of pure PLA (black), pure CAP (orange) and a 
20% weight dispersion of CAP in PLA (blue), normalized to ε’’(τα). Lines are guides to the eye. 
Right inset: Arrhenius plot of the structural relaxation time of the same three samples. Lines are 
VFT fits of the corresponding relaxation times. Left inset: DSC traces for the 20% CAP mixture, 
pure CAP and pure PLA (Tg is indicated). The baseline was subtracted from the traces. 
Conclusions 
We have measured the molecular relaxation dynamics and crystallization kinetics of the 
Chloramphenicol antibiotic. Dielectric characterization shows a fragile liquid, with dynamic 
glass transition temperature Tg = 300 K and m = 104, characterized by the presence of a 
pronounced structural relaxation (α) and a weaker secondary relaxation (γ). Recrystallization 
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kinetics experiments and SEM characterization indicate that the supercooled liquid recrystallizes 
into dendritic structures, with Avrami exponent of n = 1.3 ± 0.1. Prior to crystallization, a 
tautomer interconversion reaction takes place; this shows that the tautomerism of CAP does not 
per se prevent recrystallization of the amorphous compound, contrary to the results of ref 25. 
If the CAP sample contains initially some water and is heated to above the melting point, 
partial degradation results, which hinders recrystallization. A non-monotonous temperature 
dependence of the ionic conductivity is observed in the degraded sample, suggesting the 
presence of small-ion species. The degraded sample displays, besides the α and γ relaxations, 
also a third intermediate relaxation process, probably associated to the local dielectric relaxation 
of degradation products in the sample. This sample showed much slower recrystallization 
kinetics, which suggests that obtaining binary mixtures of CAP constitutes a possible path to 
avoid degradation while still metastabilizing the amorphous state. Hence the kinetic stability of 
some supercooled liquid CAP samples does indeed result from spatial frustration as suggested in 
ref 25, however, the spatial frustration is not a consequence of different tautomers but rather of 
hydrolysis products. If these can be shown not to be harmful, then melting and cooling CAP 
powder exposed to air can be employed as a straightforward and facile approach to obtain 
kinetically stable amorphous CAP. We further explored the effect of spatial frustration by 
dispersing CAP in poly-lactic acid: the structural relaxation time and Tg of the resulting mixture 
are intermediate between those of the two pure components, and the dispersion is found to be 
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